{"id":"W7108659049","doi":"10.1182/blood-2025-2118","title":"A post hoc safety analysis of fixed-duration acalabrutinib-venetoclax combinations vs chemoimmunotherapy: Results from the phase 3 AMPLIFY trial","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Ottawa","funders":"","keywords":"Obinutuzumab; Venetoclax; Fludarabine; Chemoimmunotherapy; Post-hoc analysis; Discontinuation; Adverse effect; Cyclophosphamide; Neutropenia","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006362136,0.001723197,0.002755977,0.0003643273,0.0002883435,0.0013209,0.001029391,0.001243794,0.007948673],"category_scores_gemma":[0.006220632,0.0004207525,0.004807763,0.0004333796,0.0007301499,0.0009486059,0.0005354689,0.002899939,0.0009307318],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008343427,"about_ca_system_score_gemma":0.001056939,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000513412,"about_ca_topic_score_gemma":0.0009191305,"domain_scores_codex":[0.9953684,0.003424675,0.0001933641,0.0004305349,0.0002618163,0.0003212766],"domain_scores_gemma":[0.9945059,0.003061353,0.001237607,0.0004867524,0.000255957,0.0004524504],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9856959,0.001353892,0.0007328601,0.000272327,0.002977269,0.00002423847,0.00002835938,0.0007244898,0.001248499,0.00009936692,0.0007458022,0.006097073],"study_design_scores_gemma":[0.7309613,0.2388461,0.009267904,0.00009053131,0.01116196,0.0001074223,0.00007726219,0.003619555,0.002408306,0.0008789399,0.002531058,0.00004970955],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.983876,0.004365677,0.001770533,0.0004130717,0.0004033835,0.002213805,0.003105001,0.0001429246,0.003709605],"genre_scores_gemma":[0.9894829,0.001031952,0.001425807,0.0006574749,0.0004440652,0.002417844,0.001934396,0.00005397186,0.002551525],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007948673,"threshold_uncertainty_score":0.03364664,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01878133108254036,"score_gpt":0.3385754346485994,"score_spread":0.319794103566059,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}